Elite Pharmaceuticals, Inc. (OTCBB:ELTP) Boosts Price with New Trial Announcement
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) is revving up its engines at the start of a new year, after flagging for a few months. ELTP grew by more than 39% on Wednesday, reaching $0.265 on dollar volumes of $5.31 million. 
ELTP boosted its rise by an announcement that it would be taking up new clinical trials of its yet undisclosed anti-addiction products. The company plans to test the drug on 52 adult subjects, in a partially randomized trial, to test for safety and side effects. ELTP has been trying to cash in on one of the so called socially significant drugs in the USA, for which the FDA may be allowing a faster acceptance procedure. The company already has anti-addiction treatments spread out through the pharmaceutical giant Actavis. 
And with all this, ELTP faces the challenge of overcoming a relatively subdued share price, by regaining the confidence of investors. ELTP spent most of 2012 in deflation mode, while 2013 marked the beginning of a rising trend, though with several deep valleys. Now, ELTP is at a three-year peak, after an extremely steep climb.
ELTP has enough long-term investors seeing a price of a few dollars in the upcoming years, based on the company’s pipeline of drugs. But ELTP also shows the possibility that without enough optimistic news, investors quickly draw the price down. So some of investors’ opinions remain cautious.
Such optimism was what lifted Titan Pharmaceuticals, Inc. (OTCBB:TTNP) to its recent attempt at gap-closing. But now TTNP is back between 60 and 70 cents, as the FDA did not give a green light to a key treatment, instead demanding wider and better- controlled trials to estimate the efficiency of implant-delivered Probuphine.
Natural Health Trends, Corp. (OTCMKTS:NHTC) was also a strong recent mover in the sector, which was boosted by appearing at an investors’ conference in San Francisco. But Wednesday came with a small retreat, as the market had already eaten up the news in anticipation of the investors’ forum.
Several pharmaceutical tickers have been active in the past week, displacing the surprising boom of cannabis stocks. While the percentage gains are back to normal, the companies hold a different, longer term promise.
Keep in mind though that not even relatively large pharmaceutical companies are immune to sharp reversals in fortune, especially if they disappoint investors. Plan the size of your investment accordingly and choose the right time frame, to avoid getting caught in the periods of lesser enthusiasm.
